Tong Ren Tang Technologies Co. Ltd. manufactures and sells Chinese medicine products in Mainland China, Hong Kong, and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||HK$5.70|
|52 Week High||HK$4.46|
|52 Week Low||HK$8.73|
|1 Month Change||-4.20%|
|3 Month Change||-8.36%|
|1 Year Change||12.65%|
|3 Year Change||-48.56%|
|5 Year Change||-60.69%|
|Change since IPO||695.35%|
Recent News & Updates
Tong Ren Tang Technologies (HKG:1666) Seems To Use Debt Rather Sparingly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
|1666||HK Pharmaceuticals||HK Market|
Return vs Industry: 1666 exceeded the Hong Kong Pharmaceuticals industry which returned -12.4% over the past year.
Return vs Market: 1666 exceeded the Hong Kong Market which returned 5.9% over the past year.
Stable Share Price: 1666 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: 1666's weekly volatility (6%) has been stable over the past year.
About the Company
|1669||3,877||Yu Wei Wang||https://www.tongrentangkj.com|
Tong Ren Tang Technologies Co. Ltd. manufactures and sells Chinese medicine products in Mainland China, Hong Kong, and internationally. The company also cultivates, purchases, and sells Chinese medicinal raw materials; produces and sells ointment, tea drinks, and foot care products; sells medicinal products; and provides medical research and development, advertisement, and Chinese medical consultation and treatment services.
Tong Ren Tang Technologies Fundamentals Summary
|1666 fundamental statistics|
Is 1666 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|1666 income statement (TTM)|
|Cost of Revenue||CN¥2.84b|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.40|
|Net Profit Margin||9.96%|
How did 1666 perform over the long term?See historical performance and comparison
3.4%Current Dividend Yield
Is Tong Ren Tang Technologies undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 1666 (HK$5.7) is trading above our estimate of fair value (HK$3.78)
Significantly Below Fair Value: 1666 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 1666 is poor value based on its PE Ratio (11.7x) compared to the Hong Kong Pharmaceuticals industry average (10x).
PE vs Market: 1666 is poor value based on its PE Ratio (11.7x) compared to the Hong Kong market (9.7x).
Price to Earnings Growth Ratio
PEG Ratio: 1666 is poor value based on its PEG Ratio (1.8x)
Price to Book Ratio
PB vs Industry: 1666's PB Ratio (1x) is in line with the HK Pharmaceuticals industry average.
How is Tong Ren Tang Technologies forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1666's forecast earnings growth (6.7% per year) is above the savings rate (1.5%).
Earnings vs Market: 1666's earnings (6.7% per year) are forecast to grow slower than the Hong Kong market (17.6% per year).
High Growth Earnings: 1666's earnings are forecast to grow, but not significantly.
Revenue vs Market: 1666's revenue (9.7% per year) is forecast to grow slower than the Hong Kong market (12.5% per year).
High Growth Revenue: 1666's revenue (9.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1666's Return on Equity is forecast to be low in 3 years time (8.7%).
How has Tong Ren Tang Technologies performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 1666 has high quality earnings.
Growing Profit Margin: 1666's current net profit margins (10%) are higher than last year (7.2%).
Past Earnings Growth Analysis
Earnings Trend: 1666's earnings have declined by 8.4% per year over the past 5 years.
Accelerating Growth: 1666's earnings growth over the past year (66.7%) exceeds its 5-year average (-8.4% per year).
Earnings vs Industry: 1666 earnings growth over the past year (66.7%) exceeded the Pharmaceuticals industry 23.8%.
Return on Equity
High ROE: 1666's Return on Equity (10.8%) is considered low.
How is Tong Ren Tang Technologies's financial position?
Financial Position Analysis
Short Term Liabilities: 1666's short term assets (CN¥8.7B) exceed its short term liabilities (CN¥3.3B).
Long Term Liabilities: 1666's short term assets (CN¥8.7B) exceed its long term liabilities (CN¥994.5M).
Debt to Equity History and Analysis
Debt Level: 1666's debt to equity ratio (29.7%) is considered satisfactory.
Reducing Debt: 1666's debt to equity ratio has increased from 3.9% to 29.7% over the past 5 years.
Debt Coverage: 1666's debt is well covered by operating cash flow (23.6%).
Interest Coverage: 1666's interest payments on its debt are well covered by EBIT (50x coverage).
What is Tong Ren Tang Technologies's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 1666's dividend (3.42%) is higher than the bottom 25% of dividend payers in the Hong Kong market (2.22%).
High Dividend: 1666's dividend (3.42%) is low compared to the top 25% of dividend payers in the Hong Kong market (6.77%).
Stability and Growth of Payments
Stable Dividend: 1666's dividends per share have been stable in the past 10 years.
Growing Dividend: 1666's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (40.1%), 1666's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Yu Wei Wang (50 yo)
Mr. Yu Wei Wang serves as Secretary of the Board at Aerospace Hi-Tech Holding Group Co., Ltd. (alternate name: Harbin Fenghua-Aerospace Hi-Tech Co. Ltd.). Mr. Wang has been the General Manager at Tong Ren...
CEO Compensation Analysis
Compensation vs Market: Yu Wei's total compensation ($USD266.89K) is below average for companies of similar size in the Hong Kong market ($USD442.19K).
Compensation vs Earnings: Yu Wei's compensation has been consistent with company performance over the past year.
Experienced Management: 1666's management team is considered experienced (2.3 years average tenure).
Experienced Board: 1666's board of directors are considered experienced (3.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Tong Ren Tang Technologies Co. Ltd.'s employee growth, exchange listings and data sources
- Name: Tong Ren Tang Technologies Co. Ltd.
- Ticker: 1666
- Exchange: SEHK
- Founded: 1669
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: HK$7.300b
- Shares outstanding: 1.28b
- Website: https://www.tongrentangkj.com
Number of Employees
- Tong Ren Tang Technologies Co. Ltd.
- No. 20 Nansanhuan Zhonglu Road
- Fengtai District
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/23 10:04|
|End of Day Share Price||2021/10/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.